CSPCY.US CSPC Pharmaceutical Group Limited
- Market cap
- USD 11.5B
- P/E
- 10.9x
- P/B
- 2.18x
- ROE
- 64.1%
- Dividend yield
- 3.90%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CSPCY.US undervalued?
Graham numberCSPCY.US trades 3.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CSPC Pharmaceutical Group Limited fundamental analysis
No fundamental analysis for CSPC Pharmaceutical Group Limited yet.
CSPC Pharmaceutical Group Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enx…
Full company profileCSPC Pharmaceutical Group Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CSPC Pharmaceutical Group Limited annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.1B | 12.9B | 18.5B | 22.1B | 24.9B | 27.9B | 30.9B | 34.6B | 29.0B | 25.3B | 73.6B |
| Gross Profit | 5.65B | 7.81B | 12.2B | 15.9B | 18.7B | 21.1B | 22.3B | 24.4B | 20.3B | 16.6B | 56.0B |
| Operating Income | 2.35B | 2.89B | 3.98B | 4.60B | 5.46B | 6.25B | 6.91B | 7.68B | 5.43B | 3.86B | 29.1B |
| EBITDA | 2.35B | 2.89B | 3.98B | 4.71B | 7.21B | 7.03B | 8.66B | 8.53B | 6.77B | 5.27B | 31.7B |
| Net Income | 1.88B | 2.32B | 3.21B | 3.71B | 4.34B | 5.61B | 6.20B | 5.87B | 4.33B | 3.78B | 24.1B |
| EPS | 0.65 | 0.79 | 1.07 | 1.24 | 1.45 | 1.88 | 2.08 | 1.98 | 1.47 | 1.32 | 8.44 |
| Balance Sheet | |||||||||||
| Total Assets | 14.8B | 18.0B | 26.4B | 25.9B | 30.0B | 34.7B | 41.8B | 46.3B | 41.7B | 46.7B | 56.0B |
| Total Liabilities | 4.57B | 5.13B | 8.75B | 6.55B | 6.96B | 7.92B | 10.1B | 11.3B | 9.88B | 12.2B | 16.6B |
| Shareholders' Equity | 9.05B | 15.3B | 17.1B | 18.2B | 22.3B | 25.9B | 29.8B | 33.2B | 30.3B | 33.2B | 37.6B |
| Cash & Short-term Investments | 3.24B | 5.69B | 7.54B | 5.96B | 8.81B | 8.75B | 16.5B | 13.1B | 7.75B | 8.87B | 18.5B |
| Total Debt | 1.14B | 987M | 70.4M | 185M | 302M | 83.9M | 621M | 707M | 476M | 641M | 653M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.61B | 2.75B | 4.49B | 3.78B | 6.74B | 4.64B | 7.63B | 4.18B | 4.26B | 5.83B | - |
| Capital Expenditure | 1.06B | 1.02B | 2.17B | 2.12B | 1.58B | 1.76B | 2.72B | 1.89B | 2.52B | 2.28B | 1.61B |
| Free Cash Flow | 1.55B | 1.73B | 1.72B | 1.66B | 5.16B | 2.88B | 4.90B | 2.29B | 1.74B | 3.55B | - |
| Ratios | |||||||||||
| ROE | 20.8% | 15.1% | 18.7% | 20.4% | 19.5% | 21.6% | 20.8% | 17.7% | 14.3% | 11.4% | 64.1% |
| ROA | 12.7% | 12.9% | 12.1% | 14.3% | 14.5% | 16.2% | 14.8% | 12.7% | 10.4% | 8.1% | 43.0% |
| Net Profit Margin | 17.0% | 17.9% | 17.4% | 16.8% | 17.4% | 20.1% | 20.0% | 17.0% | 14.9% | 14.9% | 32.8% |
| Debt to Equity | 0.13x | 0.06x | 0.00x | 0.01x | 0.01x | 0.00x | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CSPC Pharmaceutical Group Limited dividends
- Dividend yield
- 3.90%
- Forward dividend
- 0.17 USD
- Payout ratio
- 66.2%
- Ex-dividend date
- Oct 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.50B | 0.87 | 66.2% |
| 2024 | CNY 3.23B | 1.10 | 74.7% |
| 2023 | CNY 3.00B | 1.01 | 51.1% |
| 2022 | CNY 2.10B | 0.70 | 33.8% |
| 2021 | CNY 1.69B | 0.57 | 30.1% |
| 2020 | CNY 1.53B | 0.51 | 35.2% |
| 2019 | CNY 965M | 0.32 | 26.0% |
| 2018 | CNY 891M | 0.30 | 27.8% |
| 2017 | CNY 726M | 0.25 | 31.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 8:5 on Dec 10, 2020.
Who owns CSPC Pharmaceutical Group Limited
Ownership data of CSPC Pharmaceutical Group Limited is not available yet.
CSPC Pharmaceutical Group Limited company profile
- Company name
- CSPC Pharmaceutical Group Limited
- Ticker
- CSPCY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 18,626
- Fiscal year end
- December
- Address
- No.896 Zhongshandong Street, Shijiazhuang, China, 050035
- Phone
- 86 311 8703 7015
- Website
- cspc.com.hk
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
CSPC Pharmaceutical Group Limited management
10- Mr. Dongchen CaiExecutive Chairman · born 1954
- Dr. Lei CaiCEO & Vice Chairman of the Board · born 1980
- Mr. Qingjie WeiCOO & Vice-Chairman of the Board · born 1970
- Dr. Chunlei LiExecutive Director & Chief Scientist · born 1976
- Mr. Zhenguo WangExecutive Director · born 1970
- Mr. Cuilong ZhangExecutive Director · born 1969
- Dr. Bing YaoExecutive Director · born 1977
- Mr. Xin CaiExecutive Director · born 1992
- Mr. Weiping ChenExecutive Director · born 1980
- Mr. Zhiyong QuExecutive Director · born 1982